Property in a Human Body: A Common Law Approach
-
Sarah E. Hilmer
Abstract
Introduction
Whether any property right in a human body exists remains a highly debatable and delicate topic worldwide. This sensitive issue raises more and more attention since technology develops enormously fast so that the law-makers can hardly follow, not only because of the constantly increasing development of the growing fields and research areas of medicine, but also because it seems to be a great burden on their shoulders to make proper law, which should neither be too narrow nor too broad. Thus, it remains the question where to draw the line whereby policy, moral and ethical considerations and implications needs to be taken into account.
Walter de Gruyter GmbH & Co. KG
Articles in the same Issue
- Editorial
- Biosafety Regulation Trends in Southern and Southeastern Asia
- Property in a Human Body: A Common Law Approach
- Pharmacogenomics: An In-House Advantage?
- The German Way of Dealing with “The Tragedy of the Anticommons” – Purpose-Bound Protection for Product Patents on Genetic Information in Germany
- Pharmacogenomics and Data Protection
- Development and Implications of Patent Law
- Life Sciences and Biotechnology
- Declaration on Human Cloning
- Gene Therapy in PR China: Regulations and Ethical Concerns
- Biotechnological Potential of Marine Sponges and their Associated Bacteria as Producers of New Pharmaceuticals (Part I)
Articles in the same Issue
- Editorial
- Biosafety Regulation Trends in Southern and Southeastern Asia
- Property in a Human Body: A Common Law Approach
- Pharmacogenomics: An In-House Advantage?
- The German Way of Dealing with “The Tragedy of the Anticommons” – Purpose-Bound Protection for Product Patents on Genetic Information in Germany
- Pharmacogenomics and Data Protection
- Development and Implications of Patent Law
- Life Sciences and Biotechnology
- Declaration on Human Cloning
- Gene Therapy in PR China: Regulations and Ethical Concerns
- Biotechnological Potential of Marine Sponges and their Associated Bacteria as Producers of New Pharmaceuticals (Part I)